Conflicting Narratives in a Growing Sector China’s early-stage biotech and drug development startups have been riding a seesaw of

Biotech IPOs: A Tale of Two Continents Not long ago, biotech firms queued eagerly for public markets, buoyed by cheap

You’re sitting across from a General Partner (GP) at a biotech-focused venture capital (VC) fund. They’re presenting their

The global biotech venture capital boom of the late 2010s has decisively given way to a sobering downturn. After a

Real-World Evidence (RWE) has become one of the most discussed innovations in healthcare decision-making, promising to bridge the gap between

The EuroQol EQ-5D is a bit like the IKEA flatpack of health economics—ubiquitous, relatively simple to use, but occasionally

In the spring of 2025, biotech startups find themselves navigating an increasingly treacherous fundraising landscape. While headlines boast of massive

Family offices are often portrayed as paragons of “patient capital,” stewards of dynastic wealth with investment horizons stretching across generations.

Biotech companies often face a critical funding gap: bringing a new therapy from lab to market is exceedingly expensive, yet

Venture capital, like most human activities involving large sums of money and delayed gratification, has developed a hierarchy. At the